{"id":60597,"date":"2024-10-16T12:04:52","date_gmt":"2024-10-16T12:04:52","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/10\/16\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/"},"modified":"2024-10-16T12:04:52","modified_gmt":"2024-10-16T12:04:52","slug":"corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/","title":{"rendered":"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)"},"content":{"rendered":"<div>\n<p align=\"justify\">NORWOOD, Mass., Oct.  16, 2024  (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this open label study <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Nn5ml121nuuB4iVxNUo7bRE6ZTXxsX9wbXEy0KqOBTgYoMtn9TpraXhp5reHRojQRyYT_I7bAPvtzl-4N5s_cxHTEEQ41uBenUfha921SH1o8FfgLs0Rb9NtUEo-Jqq-Djyt6DrKLsIBMD-6NsQk_w==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"(NCT06265727)\">(NCT06265727)<\/a> is being conducted in the US and the UK. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the Phase 1 study is evaluating four predetermined doses (1.8 mg\/kg, 2.7 mg\/kg, 3.6 mg\/kg and 4.5 mg\/kg) and will be followed by Part B (dose optimization) and Part C (dose expansion) that will determine recommended\/optimized doses and seek preliminary efficacy signals.<\/p>\n<p align=\"justify\">The company expects to share the first data from dose escalation in Q1 2025.<\/p>\n<p align=\"justify\"><strong>About CRB-701<\/strong><br \/>CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer.<\/p>\n<p align=\"justify\"><strong>About Corbus<\/strong><br \/>Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus\u2019 pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF\u03b2 expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yOZj-GClwg_hZ89xFuBhk_aDaU_huhUSFlJdbKJ33aJf6fLhKZhCTPddsOsp0nndHXCV504pE8pYGFG8Nxnfq_gaVdE6IA0WZp2nc48swMQ=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>Facebook<\/u><\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l6uQ_K414WufMyXQVLU9bVX_q6cpRZ3VnBVPw5Ihkpegc3J6ecE0mSOdYvxqvBOioAMCIW6rA7_IJ7e22cFOM_PP0C60r5GPk71qMD6VYG5Mt300VxkwWVbvwjH3A0_2\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>LinkedIn<\/u><\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-_kDcZuAgyfnNqS6H39C4MAXtkxj200bk1AEwiNgLpIjt7IuE_q2hSow8rshtJHFCNSMUxJ2_WruWG87atV7fA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><u>X<\/u><\/a>.<\/p>\n<p align=\"justify\"><strong>Forward-Looking Statements <\/strong><br \/>This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company&#8217;s trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management&#8217;s current beliefs and assumptions.<\/p>\n<p align=\"justify\">These statements may be identified by the use of forward-looking expressions, including, but not limited to, &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;potential,\u201d &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company&#8217;s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p align=\"justify\">All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.<\/p>\n<p align=\"justify\"><strong><u>INVESTOR CONTACT: <\/u><\/strong><\/p>\n<p align=\"justify\"><strong>Sean Moran<\/strong><br \/><em>Chief Financial Officer<\/em><br \/>Corbus Pharmaceuticals<br \/>smoran@corbuspharma.com<\/p>\n<p><strong>Bruce Mackle<\/strong><br \/><em>Managing Director<\/em><br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=e1Jr_X6rlTpIWwbGayqXJDByHYQ1FVHcc7xNhzUr1uDwKduzXvSxYxBTNZ30R8DbC5bgEuix_V-Bfqi3Gd-JS1UJtax6xht8hu4T2eG8Rl-A6UsTVRZl8opDL1sYmZkt\" rel=\"nofollow noopener\" target=\"_blank\" title=\"bmackle@lifesciadvisors.com\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NzYxODY0ZGEtMWExNC00MDNiLWIyYTItZTk5Y2NmNzZiN2Q1LTUwMDExODg0MA==\/tiny\/Corbus-Pharmaceuticals-Holding.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), an oncology and obesity company with a diversified portfolio, announced today that it has completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002). The dose escalation part of this [&#8230;]\n","protected":false},"author":1,"featured_media":60598,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60597","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)\" \/>\n<meta property=\"og:description\" content=\"NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), an on\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-16T12:04:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Corbus-Pharmaceuticals-Holding.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)\",\"datePublished\":\"2024-10-16T12:04:52+00:00\",\"dateModified\":\"2024-10-16T12:04:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/\"},\"wordCount\":625,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/\",\"name\":\"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-10-16T12:04:52+00:00\",\"dateModified\":\"2024-10-16T12:04:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/","og_locale":"en_US","og_type":"article","og_title":"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)","og_description":"NORWOOD, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) &#8212; Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), an on","og_url":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-10-16T12:04:52+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Corbus-Pharmaceuticals-Holding.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)","datePublished":"2024-10-16T12:04:52+00:00","dateModified":"2024-10-16T12:04:52+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/"},"wordCount":625,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/","url":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/","name":"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701) - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-10-16T12:04:52+00:00","dateModified":"2024-10-16T12:04:52+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/corbus-announces-enrollment-completion-of-dose-escalation-stage-of-phase-1-clinical-trial-of-its-next-generation-nectin-4-targeting-adc-crb-701\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=60597"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60597\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/60598"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=60597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=60597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=60597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}